CREATE Medicines, Inc. has announced preclinical data showing that its in vivo CAR-T platform achieved complete B cell depletion in non-human primates using a proprietary mRNA-LNP delivery system. The results, which include repeat dosing capabilities and receptor-specific targeting, were presented at the Keystone Symposia: Emerging Cell Therapies conference. This update follows earlier validation in humans and sets the stage for clinical entry in the second half of 2026.

What this signals about the scalability of in vivo CAR-T beyond oncology settings

The significance of CREATE Medicines’ platform lies not just in its anti-B cell efficacy, but in its redosable architecture—an aspect many in vivo CAR-T developers have struggled to demonstrate reliably. By successfully depleting B cells in a large animal model using both a TCR-specific chimeric antigen receptor and a 41BBζ-based construct, the data affirm that the company’s LNP-based RNA payload delivery can modulate T cells repeatedly in vivo without inducing immune clearance or systemic toxicity.

Repeat dosing is often regarded as a litmus test for the practical utility of any in vivo cell engineering platform. Many RNA- and LNP-based technologies, while effective in a single administration, trigger immune recognition that impedes subsequent doses. CREATE’s data suggest that its vector and payload structure may circumvent this barrier—an outcome that, if confirmed in humans, would dramatically increase the therapeutic scope of in vivo CAR-T therapies.

The therapeutic implications for autoimmune diseases are substantial. Conditions such as systemic lupus erythematosus, multiple sclerosis, and pemphigus vulgaris may require iterative or cyclical B cell suppression to maintain durable remission. Current regimens using anti-CD20 monoclonal antibodies like rituximab or ocrelizumab offer partial depletion and are associated with prolonged B cell aplasia and infectious risk. An RNA-programmed CAR-T system that can be selectively deployed and withdrawn based on disease activity could represent a paradigm shift.

Why the modular receptor architecture is being closely watched by competitors

CREATE Medicines’ platform integrates chimeric receptors directly into the endogenous T cell receptor complex. This design allows for tighter control of signal strength, co-stimulatory engagement, and immune exhaustion profiles, which are critical variables in both efficacy and safety. By anchoring the CAR into the TCR rather than expressing it as an independent surface receptor, the system may better mimic native immune logic and reduce aberrant activation.

This could be especially relevant in autoimmune indications, where over-activation or misfiring of effector T cells could worsen inflammation or precipitate off-target cytotoxicity. Industry observers suggest that this endogenous tuning mechanism, if effective, may allow CREATE to extend its technology to regulatory T cells or helper T cell subsets for tolerance induction—domains that remain largely untapped in the current CAR-T field.

For oncology, the flexibility to customize signaling domains and persistence controls may enhance tumor infiltration, reduce antigen escape, and mitigate on-target/off-tumor effects. Modular CAR design has long been pursued by companies like Allogene Therapeutics, Poseida Therapeutics, and Autolus Therapeutics, but most remain tied to ex vivo engineering workflows. CREATE’s ability to achieve this modularity in vivo may place it in a distinct category of platform innovators.

How this platform could reshape CAR-T economics and manufacturing burden

The promise of in vivo CAR-T has always been about democratization: removing the centralized manufacturing chokepoint and delivering immune reprogramming at scale. Traditional autologous CAR-T therapies require leukapheresis, viral transduction, and cell expansion, all of which contribute to high costs, narrow geographic accessibility, and treatment delays.

CREATE’s mRNA-LNP approach eliminates these constraints. Instead of producing and delivering engineered cells, the company administers a targeted RNA payload that programs T cells inside the patient’s body. This could dramatically reduce cost per dose and expand access to regions without advanced cell therapy infrastructure.

Additionally, by relying on synthetic, non-viral components, CREATE avoids the batch variability and regulatory complexity associated with lentiviral and retroviral vectors. The potential to stockpile off-the-shelf RNA-LNP doses could also accelerate emergency use deployment in acute conditions, such as cytokine storm syndromes or post-transplant lymphoproliferative disease.

Yet there are still questions about durability and long-term persistence. Unlike permanently engineered CAR-T cells, RNA-based CARs typically express transiently. While this may offer a favorable safety profile, it also raises questions about how frequently dosing would be required to maintain disease control—especially in high-burden cancers or refractory autoimmune cases.

What clinical entry in 2026 will likely hinge on from a risk standpoint

Clinical translation of in vivo CAR-T will depend heavily on how well preclinical advantages hold up in human immune systems. One of the most critical variables is immunogenicity. While non-human primates provide a reasonable approximation of human immune responses, they do not fully capture the variability seen across human populations, particularly with respect to innate recognition of LNP carriers and adaptive responses to repetitive mRNA antigens.

Another potential hurdle is end-organ toxicity. While no overt toxicity was reported in the primate model, even targeted B cell depletion can lead to hypogammaglobulinemia, delayed infections, or reactivation of latent viruses. Regulators will likely require extended monitoring protocols for early-stage trials to track these outcomes.

Toxicology studies will also need to address potential off-target effects of the LNP formulation, particularly in organs with high vascularity like the liver and spleen. The biodistribution of lipid nanoparticles has historically been a challenge for gene delivery platforms, and safety thresholds may vary depending on the route of administration and frequency of re-dosing.

From a regulatory standpoint, the classification of this therapy could influence trial design. If treated as a gene therapy, the program would fall under FDA’s Office of Tissues and Advanced Therapies and be subject to gene therapy-specific guidelines. However, if the platform is positioned more akin to RNA therapeutics, the path may involve less burdensome monitoring requirements.

What this means for the autoimmune and hematologic malignancy pipeline landscape

CREATE Medicines appears to be carving out a dual-market strategy, targeting both oncology and immune-mediated diseases—a rare positioning in the CAR-T space. Most competitors focus on either cancer (e.g., CD19, BCMA) or autoimmunity (e.g., CD19 in lupus), but not both. By anchoring its platform in receptor modularity and redosable delivery, CREATE is attempting to blur the lines between these therapeutic areas.

In hematologic malignancies, the in vivo approach could serve as a bridge therapy or consolidation regimen after initial cytoreduction with standard chemotherapy or monoclonal antibodies. For example, in chronic lymphocytic leukemia or diffuse large B-cell lymphoma, patients with high-risk molecular features might benefit from periodic CAR-T reprogramming to sustain remission.

In autoimmunity, where disease flare-ups are episodic and often unpredictable, the ability to deliver short bursts of CAR activity without long-term suppression may prove advantageous. It would also sidestep the immunosuppressive baggage carried by chronic steroid or biologic use. However, the ability to tailor CAR constructs to disease-specific antigens—many of which remain poorly characterized—will be crucial to success in this space.

As other players like Sangamo Therapeutics, ArsenalBio, and Capstan Therapeutics push deeper into the in vivo cell engineering field, the race is now less about proof of concept and more about regulatory clarity, manufacturing robustness, and therapeutic breadth.

  autoimmune therapies, B cell depletion, CAR-T manufacturing, CREATE Medicines, hematological malignancies, in vivo CAR-T, Keystone Symposia, mRNA therapy, RNA-LNP delivery